Meeting
2015 ASCO Annual Meeting
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
Authors
Charlie Gourley
University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom
Charlie Gourley , Hani Gabra , Ignace Vergote , Bristi Basu , James Brenton , Mikael Von Euler , Ulf Björklund , Austin M. Smith , John Green
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02098343
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS5605)
DOI
10.1200/jco.2015.33.15_suppl.tps5605
Abstract #
TPS5605
Poster Bd #
163a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
First Author: Amit M. Oza
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels
Poster
2016 ASCO Annual Meeting
PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
First Author: Charlie Gourley
Poster
2011 ASCO Annual Meeting
The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC).
First Author: I. Pokataev